A human acute lymphoblastic leukemia line with the T(4;11) translocation as a model of minimal residual disease in SCID mice.

[1]  A. Pileri,et al.  High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[2]  F. Uckun.  Severe combined immunodeficient mouse models of human leukemia. , 1996, Blood.

[3]  F. Lo Coco,et al.  Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL‐1/AF‐4 positive‐acute lymphoblastic leukaemia , 1996, British journal of haematology.

[4]  G. Basso,et al.  Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Tuel-ahlgren,et al.  Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. , 1995, Blood.

[6]  R. Larson,et al.  A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. , 1995, Blood.

[7]  T. Barbui,et al.  Establishment of human acute myelogenous leukemia lines secreting interleukin‐1β in SCID mice , 1995, International journal of cancer.

[8]  D. Campana,et al.  Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. , 1995, Blood.

[9]  J. Downing,et al.  Human t(4;11)(q21;q23) acute lymphoblastic leukemia in mice with severe combined immunodeficiency. , 1994, Blood.

[10]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[11]  T. Barbui,et al.  Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. , 1993, Blood.

[12]  M. Boccadoro,et al.  Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. , 1993, Bone marrow transplantation.

[13]  T. Barbui,et al.  Human T-cell lymphoblastic lymphoma expressing the T-cell receptor gamma/delta established in immune-deficient (bg/nu/xid) mice. , 1993, Leukemia.

[14]  G. Zon,et al.  In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  C. Riccardi,et al.  Growth and spread of human malignant T lymphoblasts in immunosuppressed nude mice: a model for meningeal leukemia. , 1992, Blood.

[16]  C. Sawyers,et al.  Propagation of human blastic myeloid leukemias in the SCID mouse. , 1992, Blood.

[17]  F. Uckun,et al.  Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin. , 1992, Cancer research.

[18]  S. Kamel‐Reid,et al.  Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice. , 1991, Blood.

[19]  B. Lange,et al.  Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice. , 1991, Blood.

[20]  J J Shuster,et al.  Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. , 1991, Blood.

[21]  H. Skipper,et al.  EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. , 1964, Cancer chemotherapy reports.

[22]  H. Skipper,et al.  Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. , 1963, Cancer research.

[23]  A. Biondi,et al.  Polymerase chain reaction (PCR) approach for the evaluation of minimal residual disease in acute leukemia , 1994, Stem cells.

[24]  W. Kamps,et al.  Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM Family" Cooperative Group. , 1992, Medical and pediatric oncology.

[25]  W. Bleyer,et al.  Biology and pathogenesis of CNS leukemia. , 1989, The American journal of pediatric hematology/oncology.